Valutazione dell'efficacia e della sicurezza di PT027 rispetto a PT007 somministrato secondo necessità in partecipanti di età compresa tra 12 e < 18 anni con asma (ACADIA)
Uno studio randomizzato, in doppio cieco, multicentrico, a gruppi paralleli, di fase IIIb di 52 settimane che valuta l'efficacia e la sicurezza di PT027 rispetto a PT007 somministrato secondo necessità in partecipanti di età compresa tra 12 e < 18 anni con asma (ACADIA)
The purpose of this study is to compare the effect of budesonide/albuterol metered-dose inhaler (BDA MDI) with albuterol sulfate metered-dose inhaler (AS MDI), both administered as needed, on the annualized rate of severe asthma exacerbations in adolescents with a documented clinical diagnosis of asthma and at least one severe exacerbation in the prior year.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This is a randomized, double-blind, multicenter, parallel-group Phase IIIb study with a fixed treatment period of 52 weeks.
The study will consist of 3 periods:
- Screening period (7 to 28 days)
- Treatment period of 52 weeks
- Safety follow-up period (7 to 14 days after the end of treatment [EOT] visit)
Participants who meet the eligibility criteria will be randomly assigned to BDA MDI 160/180 micrograms (μg) or AS MDI 180 μg treatment groups in a 1:1 ratio on top of their own usual maintenance therapy during treatment period.
This study will also include a pharmacokinetic (PK) sub-study with single visit scheduled after the safety follow-up visit in the main study. During PK sub-study, single dose of open-label BDA MDI 160/180 μg will be administered.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 3
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: AstraZeneca Clinical Study Information Center
- Numero di telefono: 1-877-240-9479
- Email: information.center@astrazeneca.com
Luoghi di studio
-
-
-
Beijing, Cina, 100191
- Reclutamento
- Research Site
-
Beijing, Cina, 100050
- Reclutamento
- Research Site
-
Bengbu, Cina, 233004
- Reclutamento
- Research Site
-
Chengdu, Cina, 610066
- Reclutamento
- Research Site
-
Chongqing, Cina, 401122
- Reclutamento
- Research Site
-
Hohhot, Cina, 10050
- Reclutamento
- Research Site
-
Mianyang, Cina, 621000
- Reclutamento
- Research Site
-
Shanghai, Cina, 200433
- Reclutamento
- Research Site
-
Shanghai, Cina
- Reclutamento
- Research Site
-
Shanghai, Cina, 200062
- Reclutamento
- Research Site
-
Shantou, Cina, 515041
- Reclutamento
- Research Site
-
Shenyang, Cina, 110004
- Reclutamento
- Research Site
-
Shenzhen, Cina, 518026
- Reclutamento
- Research Site
-
Suzhou, Cina, 215002
- Reclutamento
- Research Site
-
Taizhou, Cina, 318000
- Reclutamento
- Research Site
-
Tianjin, Cina, 300211
- Reclutamento
- Research Site
-
Tianjin, Cina, 300134
- Reclutamento
- Research Site
-
Tianjin, Cina, 300050
- Reclutamento
- Research Site
-
Wuhan, Cina, 430000
- Reclutamento
- Research Site
-
Yanji, Cina, 133000
- Reclutamento
- Research Site
-
Yantai, Cina, 264000
- Reclutamento
- Research Site
-
Zhongshan, Cina, 528400
- Reclutamento
- Research Site
-
-
-
-
-
Chihuahua City, Messico, 31000
- Reclutamento
- Research Site
-
Chihuahua City, Messico, 31238
- Reclutamento
- Research Site
-
Guadalajara, Messico, 44100
- Reclutamento
- Research Site
-
Guadalajara, Messico, 44500
- Reclutamento
- Research Site
-
Monterrey, Messico, 64465
- Reclutamento
- Research Site
-
-
-
-
Alaska
-
Anchorage, Alaska, Stati Uniti, 99508
- Reclutamento
- Research Site
-
-
Arizona
-
Gilbert, Arizona, Stati Uniti, 85234
- Reclutamento
- Research Site
-
Phoenix, Arizona, Stati Uniti, 85016
- Reclutamento
- Research Site
-
-
Arkansas
-
Little Rock, Arkansas, Stati Uniti, 72202
- Completato
- Research Site
-
-
California
-
Huntington Beach, California, Stati Uniti, 92647
- Non ancora reclutamento
- Research Site
-
Huntington Beach, California, Stati Uniti, 92648
- Non ancora reclutamento
- Research Site
-
Long Beach, California, Stati Uniti, 90806
- Reclutamento
- Research Site
-
Long Beach, California, Stati Uniti, 90815
- Reclutamento
- Research Site
-
Madera, California, Stati Uniti, 93636
- Non ancora reclutamento
- Research Site
-
Mission Viejo, California, Stati Uniti, 92691
- Reclutamento
- Research Site
-
Moreno Valley, California, Stati Uniti, 92553
- Reclutamento
- Research Site
-
Orange, California, Stati Uniti, 92868
- Reclutamento
- Research Site
-
Redondo Beach, California, Stati Uniti, 90277
- Reclutamento
- Research Site
-
Riverside, California, Stati Uniti, 92506
- Reclutamento
- Research Site
-
San Diego, California, Stati Uniti, 92123
- Non ancora reclutamento
- Research Site
-
San Diego, California, Stati Uniti, 92123
- Reclutamento
- Research Site
-
San Francisco, California, Stati Uniti, 94143
- Ritirato
- Research Site
-
Westminster, California, Stati Uniti, 92683
- Reclutamento
- Research Site
-
-
Colorado
-
Denver, Colorado, Stati Uniti, 80206
- Reclutamento
- Research Site
-
-
Delaware
-
Wilmington, Delaware, Stati Uniti, 19803
- Reclutamento
- Research Site
-
-
Florida
-
Destin, Florida, Stati Uniti, 32541
- Reclutamento
- Research Site
-
Jacksonville, Florida, Stati Uniti, 32207
- Reclutamento
- Research Site
-
Kendall, Florida, Stati Uniti, 33176
- Non ancora reclutamento
- Research Site
-
Largo, Florida, Stati Uniti, 33777
- Completato
- Research Site
-
Miami, Florida, Stati Uniti, 33144
- Reclutamento
- Research Site
-
Miami, Florida, Stati Uniti, 33145
- Reclutamento
- Research Site
-
Miami, Florida, Stati Uniti, 33185
- Reclutamento
- Research Site
-
Miami, Florida, Stati Uniti, 33142
- Reclutamento
- Research Site
-
Miami, Florida, Stati Uniti, 33183
- Reclutamento
- Research Site
-
Orlando, Florida, Stati Uniti, 32827
- Non ancora reclutamento
- Research Site
-
Pembroke Pines, Florida, Stati Uniti, 33026
- Reclutamento
- Research Site
-
Tampa, Florida, Stati Uniti, 33613
- Ritirato
- Research Site
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30329
- Reclutamento
- Research Site
-
Columbus, Georgia, Stati Uniti, 31904
- Reclutamento
- Research Site
-
Fayetteville, Georgia, Stati Uniti, 30214
- Reclutamento
- Research Site
-
Snellville, Georgia, Stati Uniti, 30078
- Reclutamento
- Research Site
-
-
Idaho
-
Meridian, Idaho, Stati Uniti, 83646
- Ritirato
- Research Site
-
-
Illinois
-
Normal, Illinois, Stati Uniti, 61761
- Reclutamento
- Research Site
-
River Forest, Illinois, Stati Uniti, 60305
- Ritirato
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti, 46202
- Reclutamento
- Research Site
-
-
Kansas
-
Kansas City, Kansas, Stati Uniti, 66160
- Reclutamento
- Research Site
-
Overland Park, Kansas, Stati Uniti, 66213
- Non ancora reclutamento
- Research Site
-
-
Kentucky
-
Louisville, Kentucky, Stati Uniti, 40217
- Reclutamento
- Research Site
-
Louisville, Kentucky, Stati Uniti, 40202
- Reclutamento
- Research Site
-
-
Louisiana
-
Lafayette, Louisiana, Stati Uniti, 70508
- Reclutamento
- Research Site
-
New Orleans, Louisiana, Stati Uniti, 70121
- Reclutamento
- Research Site
-
New Orleans, Louisiana, Stati Uniti, 70125
- Reclutamento
- Research Site
-
-
Maryland
-
Ellicott City, Maryland, Stati Uniti, 21043
- Reclutamento
- Research Site
-
Lanham, Maryland, Stati Uniti, 20706
- Non ancora reclutamento
- Research Site
-
Silver Spring, Maryland, Stati Uniti, 20902
- Reclutamento
- Research Site
-
White Marsh, Maryland, Stati Uniti, 21162
- Reclutamento
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02114
- Non ancora reclutamento
- Research Site
-
-
Michigan
-
Detroit, Michigan, Stati Uniti, 48201
- Reclutamento
- Research Site
-
-
Minnesota
-
Mankato, Minnesota, Stati Uniti, 56001
- Attivo, non reclutante
- Research Site
-
-
Missouri
-
Kansas City, Missouri, Stati Uniti, 64118
- Reclutamento
- Research Site
-
Kansas City, Missouri, Stati Uniti, 64108
- Ritirato
- Research Site
-
St Louis, Missouri, Stati Uniti, 63108
- Reclutamento
- Research Site
-
-
Montana
-
Missoula, Montana, Stati Uniti, 59804
- Reclutamento
- Research Site
-
-
Nebraska
-
Lincoln, Nebraska, Stati Uniti, 68510
- Reclutamento
- Research Site
-
Lincoln, Nebraska, Stati Uniti, 68516
- Reclutamento
- Research Site
-
Omaha, Nebraska, Stati Uniti, 68114
- Reclutamento
- Research Site
-
-
New Jersey
-
Newark, New Jersey, Stati Uniti, 07103
- Reclutamento
- Research Site
-
Newark, New Jersey, Stati Uniti, 07103
- Non ancora reclutamento
- Research Site
-
Northfield, New Jersey, Stati Uniti, 08225
- Reclutamento
- Research Site
-
Ocean City, New Jersey, Stati Uniti, 07712
- Reclutamento
- Research Site
-
Paramus, New Jersey, Stati Uniti, 07652
- Reclutamento
- Research Site
-
-
New Mexico
-
Albuquerque, New Mexico, Stati Uniti, 87106
- Reclutamento
- Research Site
-
-
New York
-
Albany, New York, Stati Uniti, 12208
- Reclutamento
- Research Site
-
Cortland, New York, Stati Uniti, 13045
- Reclutamento
- Research Site
-
Hawthorne, New York, Stati Uniti, 10532
- Reclutamento
- Research Site
-
Hollis, New York, Stati Uniti, 11423
- Ritirato
- Research Site
-
New York, New York, Stati Uniti, 10032
- Reclutamento
- Research Site
-
New York, New York, Stati Uniti, 11355
- Reclutamento
- Research Site
-
New York, New York, Stati Uniti, 10019
- Ritirato
- Research Site
-
Rochester, New York, Stati Uniti, 14607
- Completato
- Research Site
-
The Bronx, New York, Stati Uniti, 10459
- Reclutamento
- Research Site
-
The Bronx, New York, Stati Uniti, 10461
- Reclutamento
- Research Site
-
Vestal, New York, Stati Uniti, 13850
- Reclutamento
- Research Site
-
Vestal, New York, Stati Uniti, 13850
- Ritirato
- Research Site
-
Watertown, New York, Stati Uniti, 13601
- Reclutamento
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, Stati Uniti, 28277
- Ritirato
- Research Site
-
Durham, North Carolina, Stati Uniti, 27705
- Non ancora reclutamento
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45229
- Non ancora reclutamento
- Research Site
-
Columbus, Ohio, Stati Uniti, 43205
- Non ancora reclutamento
- Research Site
-
Columbus, Ohio, Stati Uniti, 43228
- Reclutamento
- Research Site
-
Dayton, Ohio, Stati Uniti, 45424
- Reclutamento
- Research Site
-
Findlay, Ohio, Stati Uniti, 45840
- Reclutamento
- Research Site
-
Toledo, Ohio, Stati Uniti, 43617
- Reclutamento
- Research Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti, 73120
- Reclutamento
- Research Site
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- Reclutamento
- Research Site
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- Non ancora reclutamento
- Research Site
-
Yukon, Oklahoma, Stati Uniti, 73099
- Reclutamento
- Research Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Stati Uniti, 15241
- Reclutamento
- Research Site
-
-
South Carolina
-
Charleston, South Carolina, Stati Uniti, 29425
- Reclutamento
- Research Site
-
Rock Hill, South Carolina, Stati Uniti, 29730
- Completato
- Research Site
-
-
South Dakota
-
Sioux Falls, South Dakota, Stati Uniti, 57105
- Reclutamento
- Research Site
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37232
- Reclutamento
- Research Site
-
-
Texas
-
Austin, Texas, Stati Uniti, 78759
- Reclutamento
- Research Site
-
Baytown, Texas, Stati Uniti, 77521
- Reclutamento
- Research Site
-
Beaumont, Texas, Stati Uniti, 77701
- Reclutamento
- Research Site
-
Beaumont, Texas, Stati Uniti, 77702
- Reclutamento
- Research Site
-
Bellaire, Texas, Stati Uniti, 77401
- Reclutamento
- Research Site
-
Corpus Christi, Texas, Stati Uniti, 78411
- Reclutamento
- Research Site
-
Corsicana, Texas, Stati Uniti, 75110
- Reclutamento
- Research Site
-
Dallas, Texas, Stati Uniti, 75231
- Reclutamento
- Research Site
-
Dallas, Texas, Stati Uniti, 75235
- Reclutamento
- Research Site
-
El Paso, Texas, Stati Uniti, 79912
- Reclutamento
- Research Site
-
Frisco, Texas, Stati Uniti, 75034
- Ritirato
- Research Site
-
Houston, Texas, Stati Uniti, 77099
- Reclutamento
- Research Site
-
Houston, Texas, Stati Uniti, 77030
- Non ancora reclutamento
- Research Site
-
Houston, Texas, Stati Uniti, 77065
- Reclutamento
- Research Site
-
Kerrville, Texas, Stati Uniti, 78028
- Ritirato
- Research Site
-
McKinney, Texas, Stati Uniti, 75069
- Reclutamento
- Research Site
-
San Antonio, Texas, Stati Uniti, 78229
- Reclutamento
- Research Site
-
San Antonio, Texas, Stati Uniti, 78215
- Reclutamento
- Research Site
-
San Antonio, Texas, Stati Uniti, 78249
- Non ancora reclutamento
- Research Site
-
Tyler, Texas, Stati Uniti, 75708
- Completato
- Research Site
-
-
Utah
-
West Jordan, Utah, Stati Uniti, 84088
- Reclutamento
- Research Site
-
-
Vermont
-
Burlington, Vermont, Stati Uniti, 05405
- Reclutamento
- Research Site
-
-
Virginia
-
Burke, Virginia, Stati Uniti, 22015
- Ritirato
- Research Site
-
-
Washington
-
Bellingham, Washington, Stati Uniti, 98225
- Completato
- Research Site
-
Vancouver, Washington, Stati Uniti, 98664
- Reclutamento
- Research Site
-
-
-
-
-
Durban, Sud Africa, 4001
- Reclutamento
- Research Site
-
Durban, Sud Africa, 3630
- Reclutamento
- Research Site
-
Durban, Sud Africa, 4092
- Reclutamento
- Research Site
-
Krugersdorp, Sud Africa, 1739
- Reclutamento
- Research Site
-
Middelburg, Sud Africa, 1055
- Reclutamento
- Research Site
-
Panorama, Sud Africa, 7500
- Reclutamento
- Research Site
-
Somerset West, Sud Africa, 7130
- Non ancora reclutamento
- Research Site
-
Welkom, Sud Africa, 9460
- Reclutamento
- Research Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Confirmed clinical diagnosis of asthma at least 12 months.
-
Receiving one of the following scheduled asthma maintenance therapies for at least 3 months with stable dosing for at least the last one month
- Low-to-high-dose Inhaled corticosteroid(s) (ICS)
- Low-to-high-dose ICS or ICS/long-acting β2-agonist (LABA) with or without one additional maintenance therapy from the following: leukotriene receptor antagonist (LTRA), long-acting muscarinic antagonist (LAMA), or theophylline
-
Receiving inhaled short-acting β2-agonist (SABA) as needed.
-
A documented history of at least one severe asthma exacerbation within 12 months.
-
Use of Sponsor-provided albuterol sulfate inhalation aerosol medication.
-
Demonstrate acceptable MDI administration technique as assessed by the investigator; use of spacers is prohibited.
-
Able to perform acceptable and reproducible peak expiratory flow (PEF) measurements as assessed by the investigator.
-
Participants must adhere to protocol specific contraception methods.
-
Negative urine pregnancy test for participants of childbearing potential.
-
Have a BMI < 40 kg/ m^2.
-
Capable of giving assent (signing the assent form) to participate in the study which includes compliance with the requirements and restrictions. The caregiver of the patient must be capable of giving written informed consent for the patient's participation in the study. Consent and assent forms must be completed prior to any study-specific procedures.
Exclusion Criteria:
- Life-threatening asthma defined as any history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s).
- Experienced > 3 severe asthma exacerbations within 12 months before screening.
- Completed treatment for lower respiratory infection and severe asthma exacerbation with SCS within 4 weeks of screening.
- Upper respiratory infection involving antibiotic treatment not resolved.
- Current smokers, former smokers with > 10 pack-years history, or former smokers who stopped smoking < 6 months (including all forms of tobacco, e-cigarettes [vaping], and marijuana).
- Other significant lung disease, including regular or occasional use of oxygen.
- Historical or current evidence of a clinically significant disease including, but not limited to: cardiovascular, hepatic, renal, hematological, neuropsychological, endocrine, or gastrointestinal disorders.
- Cancer not in complete remission for at least 5 years.
- History or hospitalization for psychiatric disorder or attempted suicide within one year.
- Significant abuse of alcohol or drugs, in the opinion of the investigator.
- Oral corticosteroid(s) (OCS)/SCS use (any dose and any indication) within 4 weeks before Visit 1 or chronic use of OCS/SCS (≥ 3 weeks use in 3 months prior to Visit 1).
- Use of any oral SABAs within one month.
- Having a known or suspected hypersensitivity to albuterol/salbutamol, or budesonide and/or their excipients.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Budesonide/albuterol metered -dose inhaler (BDA MDI)
Participants will receive BDA MDI 160/180 μg (given as 2 puffs of 80/90 μg) as needed. |
Participants will receive oral inhalation of BDA MDI 160/180 μg taken as 2 puffs of 80/90 μg as needed.
Altri nomi:
|
|
Comparatore attivo: Albuterol sulfate metered-dose inhaler (AS MDI)
Participants will receive AS MDI 180 μg (given as 2 puffs of 90 μg) as needed. |
Participants will receive oral inhalation of AS MDI 180 μg taken as 2 puffs of 90 μg as needed.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Annualized rate of severe asthma exacerbations (AAER)
Lasso di tempo: From Randomization (Day 1) to Week 52 (EOT)
|
The effect of BDA MDI compared with AS MDI, both administered as needed, on the AAER in participants with asthma will be evaluated. |
From Randomization (Day 1) to Week 52 (EOT)
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Time to first (TTF) severe asthma exacerbation
Lasso di tempo: From Randomization (Day 1) to Week 52 (EOT)
|
The effect of BDA MDI compared with AS MDI, both administered as needed, on the risk of a first severe asthma exacerbation in participants with asthma will be evaluated. |
From Randomization (Day 1) to Week 52 (EOT)
|
|
Annualized total systemic corticosteroids (SCS) exposure for treatment of asthma
Lasso di tempo: From Randomization (Day 1) to Week 52 (EOT)
|
The effect of BDA MDI compared with AS MDI, both administered as needed, on the annualized total SCS exposure for treatment of asthma in participants with asthma will be evaluated. |
From Randomization (Day 1) to Week 52 (EOT)
|
|
Number of participants with adverse events (AEs) and severe adverse events (SAEs)
Lasso di tempo: Up to Week 52
|
The safety and tolerability of BDA MDI compared with AS MDI in participants with asthma will be assessed. |
Up to Week 52
|
|
Maximum Observed Concentration (Cmax)
Lasso di tempo: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Area under concentration-time curve from time 0 to last quantifiable concentration (AUClast)
Lasso di tempo: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Area under concentration-time curve from time 0 to infinity (AUCinf)
Lasso di tempo: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Time to reach maximum concentration following drug administration (Tmax)
Lasso di tempo: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Time of last quantifiable concentration (Tlast)
Lasso di tempo: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Terminal elimination half-life (t½λz)
Lasso di tempo: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Terminal elimination rate constant (λz)
Lasso di tempo: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Apparent total body clearance (CL/F)
Lasso di tempo: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
|
Apparent volume of distribution based on the terminal phase (Vz/F)
Lasso di tempo: At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
The PK of budesonide and albuterol in participants with asthma, following a single dose of BDA MDI will be characterized. |
At 0, 10, 20, 40 minutes and 1, 2, 4, 6, 8, 10, and 12 hours post-dose
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- D6934C00001
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Periodo di condivisione IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Criteri di accesso alla condivisione IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non negotiable contract for data accessors) must be in place before accessing requested information.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .